Drug intelligence / Profile preview

KB312

Development stage: Preclinical
Lead developer: KiRA Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

KB312 is an investigational **first-in-class, selective, immune-cell depleting monoclonal antibody** being developed by Kira Biotech for immune-mediated disorders. It is designed to target activated immune cells and restore immune homeostasis by inducing immune tolerance. Publicly described development has focused initially on **acute graft-versus-host-disease** following allogeneic hematopoietic stem cell transplant, with the program originating from research at the University of Queensland and collaborators including the University of California San Francisco and Mater Research Institute.

Beyond the preview

Go deeper on KB312.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KB312.

Explore the full profile